Cabaletta Bio, Inc. filings document regulatory disclosures for a Nasdaq-listed biotechnology issuer developing engineered T cell therapies for autoimmune diseases. Form 8-K reports cover operating and financial results, corporate presentations, material agreements, and clinical or regulatory updates involving rese-cel and the RESET clinical development program.
Proxy materials describe annual meeting voting matters and governance for holders of Cabaletta Bio common stock. The filing record also identifies the company’s registered common stock, capital-structure disclosures, risk-oriented forward-looking statements, and formal material-event reporting tied to its cell-therapy development and manufacturing strategy.
Cabaletta Bio, Inc. reported that its General Counsel, Gerard Michael, received a grant of stock options covering 175,000 shares of common stock. The options were awarded at an exercise price of $0.00 per share, reflecting a compensatory equity award rather than an open-market purchase.
According to the vesting terms, 25% of the shares subject to the option will vest and become exercisable on March 1, 2027. The remaining 75% will vest in twelve substantially equal quarterly installments after that date, conditioned on his continued service with the company on each vesting date.
Cabaletta Bio, Inc. reported that President, Science & Tech. Gwendolyn Binder acquired a grant of 225,000 stock options on March 2, 2026. These options have a stated price of $0.00 per share and represent rights to buy Cabaletta Bio common stock in the future.
According to the vesting terms, 25% of the shares underlying this option vest and become exercisable on March 1, 2027, with the remaining options vesting in twelve substantially equal quarterly installments thereafter, contingent on her continued service on each vesting date.
Cabaletta Bio, Inc. reported that Chief Medical Officer David J. Chang acquired a new stock option award covering 225,000 shares of company stock. This option was granted as a derivative security and represents his total option holdings after the reported transaction.
According to the vesting terms, 25% of the shares underlying this option will vest and become exercisable on March 1, 2027. The remaining shares will vest in twelve substantially equal quarterly installments after that date, conditioned on his continued service with the company on each vesting date.
Nichtberger Steven reported acquisition or exercise transactions in this Form 4 filing.
Cabaletta Bio reported that President and CEO Steven Nichtberger received a grant of stock options covering 674,000 shares of the company’s common stock. The options were awarded at no cost to him, increasing his directly held option position to 674,000 options after the grant.
According to the vesting terms, 25% of the shares underlying this option will vest and become exercisable on March 1, 2027. The remaining 75% will vest in twelve substantially equal quarterly installments after that date, conditioned on his continued service with the company on each vesting date.
Cabaletta Bio, Inc. reported that its Chief Financial Officer, Anup Marda, received a grant of stock options covering 225,000 shares of common stock. The options were acquired as a grant, with 25% scheduled to vest and become exercisable on March 1, 2027, and the remaining 75% vesting in twelve substantially equal quarterly installments thereafter, conditioned on his continued service with the company on each vesting date.
Cabaletta Bio, Inc. Schedule 13G reports that Millennium Management LLC, together with Millennium Group Management LLC and Israel A. Englander, beneficially hold 5,130,763 shares of common stock, representing 5.3% of the class.
The filing states the holders report shared voting power and shared dispositive power over the 5,130,763 shares and includes a Joint Filing Agreement dated February 17, 2026.
Cabaletta Bio received an updated ownership report from Alyeska-affiliated entities and Anand Parekh. They report beneficial ownership of 4,500,000 shares of Cabaletta Bio common stock through warrants, representing 4.67% of the company’s common stock, based on 96,265,204 shares outstanding as disclosed in a recent Form 10-Q.
The filing shows no sole voting or dispositive power, but shared power over all 4,500,000 shares. The reporting persons state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cabaletta Bio.
Cabaletta Bio, Inc. received an updated ownership report showing that Cormorant Asset Management, LP and Bihua Chen beneficially own 9,400,000 shares of Cabaletta Bio common stock, representing 9.28% of the class based on shares outstanding as of October 31, 2025.
The reporting persons have shared voting and dispositive power over these shares and report no sole voting or dispositive power. Their holdings include Cabaletta Bio common stock issuable upon exercise of warrants that are exercisable for up to 5,000,000 shares. They certify the position is held in the ordinary course of business and not to change or influence control of the company.
Cabaletta Bio received an amended Schedule 13G showing that T. Rowe Price Investment Management, Inc. beneficially owns 9,858,257 shares of its common stock, representing 10.2% of the class. The firm reports sole voting power over 9,804,684 shares and sole dispositive power over 9,858,257 shares.
The filing notes that these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Cabaletta Bio. T. Rowe Price Small-Cap Value Fund holds 5,169,039 shares, representing 5.4% of the common stock class reported.
Cabaletta Bio Chief Medical Officer David J. Chang reported buying 8,800 shares of Cabaletta Bio common stock on January 21, 2026. The purchase was made in an open-market transaction coded “P” at a price of $2.26 per share. After this transaction, he directly owns 8,800 common shares of the company.